GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » EV-to-EBITDA

Actavia Life Sciences (Actavia Life Sciences) EV-to-EBITDA : -3.20 (As of May. 03, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Actavia Life Sciences's enterprise value is $13.56 Mil. Actavia Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.23 Mil. Therefore, Actavia Life Sciences's EV-to-EBITDA for today is -3.20.

The historical rank and industry rank for Actavia Life Sciences's EV-to-EBITDA or its related term are showing as below:

RASP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99999999.99   Med: 0   Max: 50827.32
Current: -3.2

During the past 11 years, the highest EV-to-EBITDA of Actavia Life Sciences was 50827.32. The lowest was -99999999.99. And the median was 0.00.

RASP's EV-to-EBITDA is ranked worse than
100% of 466 companies
in the Biotechnology industry
Industry Median: 9.15 vs RASP: -3.20

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Actavia Life Sciences's stock price is $0.0173. Actavia Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.008. Therefore, Actavia Life Sciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Actavia Life Sciences EV-to-EBITDA Historical Data

The historical data trend for Actavia Life Sciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences EV-to-EBITDA Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.56 -1.13 -13.35 9.36 -3.68

Actavia Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.86 -2.83 -4.61 -3.68 -1.45

Competitive Comparison of Actavia Life Sciences's EV-to-EBITDA

For the Biotechnology subindustry, Actavia Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's EV-to-EBITDA falls into.



Actavia Life Sciences EV-to-EBITDA Calculation

Actavia Life Sciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=13.559/-4.232
=-3.20

Actavia Life Sciences's current Enterprise Value is $13.56 Mil.
Actavia Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actavia Life Sciences  (OTCPK:RASP) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Actavia Life Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0173/-0.008
=At Loss

Actavia Life Sciences's share price for today is $0.0173.
Actavia Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.008.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Actavia Life Sciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines